Cardiac safety results from a phase II, open-label, multicenter, pilot study of two docetaxel-based regimens plus bevacizumab for the adjuvant treatment of subjects with node-positive or high-risk node-negative breast cancer.
Saved in:
| Title: | Cardiac safety results from a phase II, open-label, multicenter, pilot study of two docetaxel-based regimens plus bevacizumab for the adjuvant treatment of subjects with node-positive or high-risk node-negative breast cancer. |
|---|---|
| Authors: | Hurvitz SA; University of California, Los Angeles, 10945 Le Conte Avenue, PVUB Suite 3360, Los Angeles, CA 90095 USA., Bosserman LD; Wilshire Oncology Medical Group, Inc., La Verne, CA USA., Chan D; Torrance Memorial Hospital, Redondo Beach, CA USA., Hagenstad CT; Suburban Hematology and Oncology, Lawrenceville, GA USA., Kass FC; Cancer Center of Santa Barbara, Santa Barbara, CA USA., Smith FP; Georgetown University School of Medicine, Washington, DC USA., Rodriguez GI; South Texas Oncology and Hematology, P.A., San Antonio, TX USA., Childs BH; sanofi U.S., Bridgewater, NJ USA., Slamon DJ; University of California, Los Angeles, 10945 Le Conte Avenue, PVUB Suite 3360, Los Angeles, CA 90095 USA. |
| Source: | SpringerPlus [Springerplus] 2014 May 12; Vol. 3, pp. 244. Date of Electronic Publication: 2014 May 12 (Print Publication: 2014). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: SpringerPlus Country of Publication: Switzerland NLM ID: 101597967 Publication Model: eCollection Cited Medium: Print ISSN: 2193-1801 (Print) Linking ISSN: 21931801 NLM ISO Abbreviation: Springerplus Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 24860718 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Cardiac safety results from a phase II, open-label, multicenter, pilot study of two docetaxel-based regimens plus bevacizumab for the adjuvant treatment of subjects with node-positive or high-risk node-negative breast cancer. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Hurvitz+SA%22">Hurvitz SA</searchLink>; University of California, Los Angeles, 10945 Le Conte Avenue, PVUB Suite 3360, Los Angeles, CA 90095 USA.<br /><searchLink fieldCode="AU" term="%22Bosserman+LD%22">Bosserman LD</searchLink>; Wilshire Oncology Medical Group, Inc., La Verne, CA USA.<br /><searchLink fieldCode="AU" term="%22Chan+D%22">Chan D</searchLink>; Torrance Memorial Hospital, Redondo Beach, CA USA.<br /><searchLink fieldCode="AU" term="%22Hagenstad+CT%22">Hagenstad CT</searchLink>; Suburban Hematology and Oncology, Lawrenceville, GA USA.<br /><searchLink fieldCode="AU" term="%22Kass+FC%22">Kass FC</searchLink>; Cancer Center of Santa Barbara, Santa Barbara, CA USA.<br /><searchLink fieldCode="AU" term="%22Smith+FP%22">Smith FP</searchLink>; Georgetown University School of Medicine, Washington, DC USA.<br /><searchLink fieldCode="AU" term="%22Rodriguez+GI%22">Rodriguez GI</searchLink>; South Texas Oncology and Hematology, P.A., San Antonio, TX USA.<br /><searchLink fieldCode="AU" term="%22Childs+BH%22">Childs BH</searchLink>; sanofi U.S., Bridgewater, NJ USA.<br /><searchLink fieldCode="AU" term="%22Slamon+DJ%22">Slamon DJ</searchLink>; University of California, Los Angeles, 10945 Le Conte Avenue, PVUB Suite 3360, Los Angeles, CA 90095 USA. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101597967%22">SpringerPlus</searchLink> [Springerplus] 2014 May 12; Vol. 3, pp. 244. <i>Date of Electronic Publication: </i>2014 May 12 (<i>Print Publication: </i>2014). – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22SpringerPlus%22">SpringerPlus </searchLink><i>Country of Publication: </i>Switzerland <i>NLM ID: </i>101597967 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Print <i>ISSN: </i>2193-1801 (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2221931801%22">21931801 </searchLink><i>NLM ISO Abbreviation: </i>Springerplus <i>Subsets: </i>PubMed not MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=24860718 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1186/2193-1801-3-244 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 244 Titles: – TitleFull: Cardiac safety results from a phase II, open-label, multicenter, pilot study of two docetaxel-based regimens plus bevacizumab for the adjuvant treatment of subjects with node-positive or high-risk node-negative breast cancer. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Hurvitz SA – PersonEntity: Name: NameFull: Bosserman LD – PersonEntity: Name: NameFull: Chan D – PersonEntity: Name: NameFull: Hagenstad CT – PersonEntity: Name: NameFull: Kass FC – PersonEntity: Name: NameFull: Smith FP – PersonEntity: Name: NameFull: Rodriguez GI – PersonEntity: Name: NameFull: Childs BH – PersonEntity: Name: NameFull: Slamon DJ IsPartOfRelationships: – BibEntity: Dates: – D: 12 M: 05 Text: 2014 May 12 Type: published Y: 2014 Identifiers: – Type: issn-print Value: 2193-1801 Numbering: – Type: volume Value: 3 Titles: – TitleFull: SpringerPlus Type: main |
| ResultId | 1 |